GlassScriptPhysician profile
Fortune Egbulefu
NPI 1497002471
$17,914.29
in general payments reported to CMS, 2019-2025
10 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
See the full distribution for Adult Reconstructive Orthopaedic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,454 · 2020: $8,706 · 2021: $1,127 · 2022: $1,953 · 2023: $700 · 2024: $518 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $10,490.73 | 2019-2023 | Journey II, Real Intelligence |
| Stryker Corporation | $5,225.62 | 2019-2025 | Mako, Hoffmann, Pelvis II |
| Encore Medical, LP | $1,575.84 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $162.21 | 2020-2023 | Persona |
| Exactech, INC. | $147.72 | 2021 | |
| Medacta USA, INC. | $117.88 | 2022 | |
| Orthalign INC | $103.58 | 2022 | |
| Bioventus LLC | $56.79 | 2019 | |
| Sanara Medtech INC. | $20.82 | 2024 | Celleraterx |
| Avanos Medical | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fortune Egbulefu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.